Growing up with HIV: Children, adolescents, and young adults with perinatally acquired HIV infection

Annual Review of Medicine

Volumn 61, Issue , 2010, Pages 169-185

  Hazra, Rohan ^a   Siberry, George K ^a   Mofenson, Lynne M ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Highly active antiretroviral therapy; Human immunodeficiency virus; Metabolic complications; Mother to child transmission; Pediatric HIV infection

Indexed keywords

ANTIRETROVIRUS AGENT; INSULIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ADULTHOOD; BONE DISEASE; BRAIN DISEASE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE DURATION; DRUG EFFICACY; DRUG FORMULATION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSLIPIDEMIA; EPIDEMIC; EPIDEMIOLOGICAL DATA; HEALTH CARE ACCESS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; IMMUNIZATION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; KIDNEY DISEASE; KIDNEY DYSFUNCTION; METABOLIC DISORDER; MORBIDITY; MORTALITY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPPORTUNISTIC INFECTION; OSTEOLYSIS; PATIENT COMPLIANCE; PEDIATRICS; PERINATAL PERIOD; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS REPLICATION; VIRUS TRANSMISSION; FEMALE; INFANT; MALE; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; PRESCHOOL CHILD; STATISTICS; UNITED STATES; VERTICAL TRANSMISSION;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; UNITED STATES; YOUNG ADULT;

EID: 77951884336     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.050108.151127     Document Type: Review

References (87)

1. Centers for Disease Control and Prevention. 2006. Reductioninperinatal transmissionof HIV infection\United States, 1985-2005. MMWR 55(21):592-597
2. Connor EM, Sperling RS, Gelber R, et al. 1994. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N. Engl. J. Med. 331:1173-1180 (Pubitemid 24331334)
3. Townsend CL, Cortina-Borja M, Peckham CS, et al. 2008. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 22:973-981
4. McKenna MT, HuX. 2007. Recent trendsin the incidence and morbidity that are associated with perinatal human immunodeficiency virus infection inthe United States.Am. J. Obstet. Gynecol. 197(3 Suppl.):S10-16
5. Whitmore S, Zhang X, Taylor A. 2009. Estimated number of births to HIV+ women in the U.S. Presented at Conf. Retroviruses and Opportunistic Infections, 16th, Montreal, Can., Feb. 8-11. Abstr. 924
6. Lee GM, Gortmaker SL, McIntosh K. 2006. Quality of life for children and adolescents: impact of HIV infection and antiretroviral treatment. Pediatrics 117:273-283
7. McConnell MS, Byers RH, Frederick T, et al. 2005. Trends in antiretroviral therapy use and survival rates for a large cohort of HIV-infected children and adolescents in the United States, 1989-2001. J. Acquir. Immune Defic. Syndr. 38:488-494
8. Mofenson L, Williams P, Brady M, et al. 2008. Trends in mortality in HIV-infected children in the United States\1994-2006. Presented at Int. AIDS Conf., XVIIth, Mexico City, Mexico, Aug. 3-8. Abstr. MOPE 0230
9. Judd A, Doerholt K, Tookey PA, et al. 2007. Morbidity, mortality and response to treatment in children in the United Kingdom and Ireland with perinatally-acquired HIV infection during 1996-2006: planning for teenage and adult care. Clin. Infect. Dis. 45:918-924
10. Federal Interagency Forum on Child and Family Statistics. 2008. America's children in brief: key national indicators of well-being, 2008. Available at http://www.childstats.gov/americaschildren/
11. Violari A, Cotton MF, Gibb DM, et al. 2008. Early antiretroviral therapy and mortality among HIV-infected infants. N. Engl. J. Med. 359:2233-2244
12. Abrams EJ. 2007. The unanswered question: when to initiate antiretroviral therapy in children with HIV infection. Curr. Opin. HIV AIDS 2:416-425
13. Welch SB, Gibb D. 2008. When should children with HIV infection be started on antiretroviral therapy? PLoS Med. 5:e73
14. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. 2009. Guidelines for the use of antiretroviral agents in pediatric HIV infection, Feb. 23 1-139. Available at http://aidsinfo.nih.gov/ ContentFiles/PediatricGuidelines.pdf
15. Menson EN, Walker AS, Sharland M, et al. 2006. Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study. BMJ 332:1183-1187
16. American Academy of Pediatrics Committee on Pediatric AIDS, Section on International Child Health, Havens PL, Gibb DM. 2007. Increasing antiretroviral drug access for children with HIV infection. Pediatrics 119:838-845
17. Shearer WT, Quinn TC, LaRussa P, et al. 1997. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N. Engl. J. Med. 336:1337-1342
18. Palumbo P, Wu H, Chadwick E, et al. 2007. Virologic response to potent antiretroviral therapy and modeling of HIV dynamics in early pediatric infection. J. Infect. Dis. 196:23-29
19. Walker AS, Doerholt K, Sharland M, et al. 2004. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Pediatric Study. AIDS 18:1915-1924
20. The Collaboration of Observational HIV Epidemiologic Research Europe (COHERE) Study Group. 2008. Response to combination antiretroviral therapy: variation by age. AIDS 22:1463-1473
21. Pediatric European Network for Treatment of AIDS (PENTA). 2004. Highly active antiretroviral therapy started in infants under 3 months of age: 72 week follow-up for CD4 cell count, viral load and drug resistance outcome. AIDS 18:237-245
22. Doerholt K, Duong T, Tookey P, et al. 2006. Outcomes for human immunodeficiency-virus-1-infected infants in the United Kingdom and Republic of Ireland in the era of effective antiretroviral therapy. Pediatr. Infect. Dis. J. 25:420-426
23. Persaud D, Palumbo P, Ziemniak C, et al. 2007. Early archiving and predominance of nonnucleoside reverse trancriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States. J. Infect. Dis. 195:1402-1410
24. Brogly S, Williams P, Seage GR, et al. 2005. Antiretroviral treatment in pediatric HIV infection in the United States: from clinical trials to clinical practice. JAMA 293:2213-2220
25. Van Dyke RB, Lee S, Johnson GM, et al. 2002. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics 109:e61
26. Dolezal C, Mellins C, Brackis-Cott E, et al. 2003. The reliability of reports of medical adherence from children with HIV and their adult caregivers. J. Pediatr. Psychol. 28:355-361
27. Parsons GN, Siberry GK, Parsons JK, et al. 2006. Multidisciplinary, inpatient directly observed therapy for HIV-1-infected children and adolescents failing HAART: a retrospective study. AIDS Patient Care STDs 20:275-284
28. Purdy JB, Freeman AF, Martin SC, et al. 2008. Virologic response using directly observed therapy in adolescents with HIV: an adherence tool. J. Assoc. Nurses AIDS Care 19:158-165
29. Reisner SL, Mimiaga MJ, Skeer M, et al. 2009. A review of HIV antiretroviral adherence and intervention studies among HIV-infected youth. Top. HIV Med. 17:14-25
30. Simoni JM, Montgomery A, Martin E, et al. 2007. Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. Pediatrics 119(6):e1371
31. Gona P, Van Dyke RB, Williams PL, et al. 2006. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA 296:292-300
32. Working Group on Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-Exposed and HIV-Infected Children. 2008. Guidelines for prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children [DRAFT], June 20 1-250. Available at http://aidsinfo.nih.gov/contentfiles/Pediatric OI.pdf.
33. Shanbhag MC, Rutstein RM, Zaoutis T, et al. 2005. Neurocognitive functioning in pediatric human immunodeficiency virus infection: effects of combined therapy. Arch. Pediatr. Adolesc. Med. 159:651-656
34. Chiriboga CA, Fleishman S, Champion S, et al. 2005. Incidence and prevalence of HIV encephalopathy in children with HIV infection receiving highly active antiretroviral therapy (HAART). J. Pediatr. 146:402-407
35. Nachman SA, Chernoff M, Gona P, et al. 2009. Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era. Arch. Pediatr. Adolesc. Med. 163:164-171
36. Brouwers P, Moss H, Wolters P, et al. 1990. Effect of continuous-infusion zidovudine therapy on neuropsychologic functioning in children with symptomatic human immunodeficiency virus infection. J. Pediatr. 117:980-985
37. McKinney RE Jr, Maha MA, Connor EM, et al. 1991. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group. N. Engl. J. Med. 324:1018-1025
38. Jeremy RJ, Kim S, Nozyce M, et al. 2005. Neuropsychological functioning and viral load in stable an-tiretroviral therapy-experienced HIV-infected children. Pediatrics 115:380-387
39. Smith R, Malee K, Leighty R, et al. 2006. Effects of perinatal HIV infection and associated risk factors on cognitive development among young children. Pediatrics 117:851-862
40. Gaughan DM, Hughes MD, Oleske JM, et al. 2004. Psychiatric hospitalizations among children and youths with human immunodeficiency virus infection. Pediatrics 113(6):e544-51
41. Mellins CA, Brackis-Cott E, Leu CS, et al. 2009. Rates and types of psychiatric disorders in perinatally human immunodeficiency virus-infected youth and seroreverters. J. Child. Psychol. Psychiatry. Epub ahead of print
42. Mellins CA, Smith R, O'Driscoll P, et al. 2003. High rates of behavioral problems in perinatally HIV-infected children are not linked to HIV disease. Pediatrics 111:384-393
43. Brown SC, Schoeman CJ, Bester CJ. 2005. Cardiac findingsin children admittedto a hospital general ward in South Africa: a comparison of HIV-infected and uninfected children. Cardiovasc. J. S. Afr. 16:206-210
44. Fisher SD, Easley KA, Orav EJ, et al. 2005. Mild dilated cardiomyopathy and increased left ventricular mass predict mortality: the prospective P2C2 HIV Multicenter Study. Am. Heart J. 150:439-447
45. Boccara F. 2008. Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors. AIDS 22(Suppl. 3):S19-26
46. Wohl DA, Brown TT. 2008. Management of morphologic changes associated with antiretroviral use in HIV-infected patients. J. Acquir. Immune Defic. Syndr. 49(Suppl. 2):S93-S100
47. Taylor P, Worrell C, Steinberg SM, et al. 2004. Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens. Pediatrics 114(2):e235-42
48. Dzwonek AB, Lawson MS, Cole TJ, et al. 2006. Body fat changes and lipodystrophy in HIV-infected children: impact of highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 43:121-123
49. Ene L, Goetghebuer T, Hainaut M, et al. 2007. Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study. Eur. J. Pediatr. 166:13-21
50. Beregszaszi M, Dollfus C, Levine M, et al. 2005. Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J. Acquir. Immune Defic. Syndr. 40:161-168
51. European Pediatric Lipodystrophy Group. 2004. Antiretroviral therapy, fat redistribution and hyperlipi-demia in HIV-infected children in Europe. AIDS 18:1443-1451
52. Amaya RA, Kozinetz CA, McMeans A, et al. 2002. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 21:405-410
53. Rosso R, Parodi A, d'Annunzio G, et al. 2007. Evaluation of insulin resistance in a cohort of HIV-infected youth. Eur. J. Endocrinol. 157:655-659
54. Verkauskiene R, Dollfus C, Levine M, et al. 2006. Serum adiponectin and leptin concentrations in HIV-infected children with fat redistribution syndrome. Pediatr. Res. 60:225-230
55. Lee B, Aurpibul L, Sirisanthana V, et al. 2009. Low prevalence of insulin resistance among HIV-infected children receiving nonnucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thailand. HIV Med. 10:72-78
56. Carter RJ, Wiener J, Abrams EJ, et al. 2006. Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999-2004: a longitudinal analysis. J. Acquir. Immune Defic. Syndr. 41:453-460
57. Aldrovandi GM, Lindsey JC, Jacobson DL, et al. 2009. Pediatric AIDS Clinical Trials Group P1045 team. Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. AIDS 23:661-672
58. Chantry CJ, Hughes MD, Alvero C, et al. 2008. Lipid and glucose alterations in HIV-infected children beginning or changing antiretroviral therapy. Pediatrics 122(1):e129-38
59. Tassiopoulos K, Williams PL, Seage GR 3rd, et al. 2008. Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children. J. Acquir. Immune Defic. Syndr. 47:607-614
60. Hadigan C, Purdy JB, Worrell CJ, et al. 2008. Impaired glucose tolerance and other metabolic abnormalities in adolescents and young adults with HIV infection acquired perinatally or in childhood. Presented at Conf. Retroviruses and Opportunistic Infections, 15th, Boston, Feb. 3-6. Abstr. 591
61. Kim JY, Zaoutis T, Chu J, et al. 2009. Effects of highly active antiretroviral therapy (HAART) on cholesterol in HIV-1-infected children: a retrospective cohort study. Pharmacoepidemiol. Drug Safety. Epub ahead of print
62. Tebas P. 2008. Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment options. J. Acquir. Immune Defic. Syndr.49(Suppl. 2):S86-S92
63. Samaras K. 2009. Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 50:499-505
64. Miller TL, Orav EJ, Lipshultz SE, et al. 2008. Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1. J. Pediatr. 153:491-497
65. McComsey GA, O'RiordanM,Hazen SL, et al. 2007. Increased carotid intima media thickness and cardiac biomarkers in HIV infected children. AIDS 21:921-927
66. Kavey RE, Allada V, Daniels SR, et al. 2006. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 114:2710-2738
67. Arpadi SM, HorlickM, Thornton J, et al. 2002. Bone mineral content is lowerin prepubertal HIV-infected children. J. Acquir. Immune Defic. Syndr. 29:450-454
68. Hazra R, Gafni RI, Maldarelli F, et al. 2005. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics 116:e846-54
69. Zamboni G, Antoniazzi F, Bertoldo F, et al. 2003. Altered bone metabolism in children infected with human immunodeficiency virus. Acta Paediatr. 92:12-16
70. Stagi S, Bindi G, Galluzzi F, et al. 2004. Changed bone status in human immunodeficiency virus type 1 (HIV-1) perinatally infected children is related to low serum free IGF-I. Clin. Endocrinol. 61:692-699
71. Mora S, Sala N, Bricalli D,et al. 2001. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS 15:1823-1829
72. MoraS, Zamproni I, Beccio S,etal. 2004. Longitudinal changes ofbone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children. J. Clin. Endocrinol. Metab. 89:24-28
73. Castillo AB, Tarantal AF, Watnik MR, et al. 2002. Tenofovir treatmentat 30mg/kg/day can inhibit cortical bone mineralization in growing rhesus monkeys (Macaca mulatta). J. Orthop. Res. 20:1185-1189
74. Gallant JE, Staszewski S, Pozniak AL, et al. 2004. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292:191-201
75. Gafni RI, Hazra R, Reynolds JC, et al. 2006. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 118:e711-18
76. Purdy JB, Gafni RI, Reynolds JC,etal. 2008. Decreased bone mineral density with off-label useoftenofovir in children and adolescents infected with human immunodeficiency virus. J. Pediatr. 152:582-584
77. Thomas V, Purdy J, Reynolds J, et al. 2009. Bone mineral density in adolescents infected with HIV perinatally or in early childhood: data from the NIH Intramural Program. Presented at Conf. Retroviruses and Opportunistic Infections, 16th, Montreal, Can., Feb. 8-11. Abstr. 912
78. Chaparro AI, Mitchell CD, Abitbol CL, et al. 2008. Proteinuria in children infected with the human immunodeficiency virus. J. Pediatr. 152:844-849
79. Andiman WA, Chernoff MC, MitchellC, et al. and the PACTG iDACS 617 Study Team. 2009. Incidence of persistent renal dysfunction in HIV-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors. Pediatr. Infect. Dis. J. 28(7):619-625
80. Baekken M, Os I, Sandvik L, et al. 2008. Microalbuminuria associated with indicators of inflammatory activity in an HIV-positive population. Nephrol. Dial. Transplant. 23:3130-3137
81. Szczech LA, Grunfeld C, Scherzer R, et al. 2007. Microalbuminuria in HIV infection. AIDS 21:1003-1009
82. Vigano A, Zuccotti GV, Martelli L, et al. 2007. Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study. Clin. Drug Investig. 27:573-581
83. Lesch A, Swartz L, Kagee A, et al. 2007. Pediatric HIV/AIDS disclosure: towards a developmental and process-oriented approach. AIDS Care 19:811-816
84. Committee on Pediatric AIDS and Committee on Adolescence. 2001. Adolescents and human immunodeficiency virus infection: the role of the pediatrician in prevention and intervention. Pediatrics 107:188-190
85. Butler AM, Williams PL, Howland LC, et al. 2009. Pediatric AIDS Clinical Trials Group 219C Study Team. Impact of disclosure of HIV infection on health-related quality of life among children and adolescents with HIV infection. Pediatrics 123:935-943
86. Brogly SB, Watts DH, Ylitalo N, et al. 2007. Reproductive health of adolescent girls perinatally infected with HIV. Am. J. Public Health 97:1047-1052
87. Lyon ME, Garvie PA, McCarter R, et al. 2009. Who will speak for me? Improving end-of-life decision-making for adolescents with HIV and their families. Pediatrics 123:e199-206